Clinical Trial Update: Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia [Phase 1]

View source ↗

Summary

Phase 1 trial update for marzeptacog alfa (activated), a coagulation factor VIIa variant, in adults with hemophilia showing completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Marzeptacog Alfa (Activated) (Marzeptacog alfa activated)

Snippet

Sponsor: Catalyst Biosciences | Conditions: Hemophilia A, Hemophilia B | Phase 1 | Status: COMPLETED | Results posted: 2021-07-16